Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN60,9560,98-0,67
Msft-1,00
Nokia3,75053,7995-0,41
IBM0,38
Mercedes-Benz Group AG57,5357,550,77
PFE-0,27
19.09.2024 1:38:53
Indexy online
AD Index online
select
AD Index online
 

  • 18.09.2024 22:00:00
Axsome Therapeutics (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
91,54 0,66 0,60 341 599
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.09.2024
Popis společnosti
Obecné informace
Název společnostiAxsome Therapeutics Inc
TickerAXSM
Kmenové akcie:Ordinary Shares
RICAXSM.O
ISIN-
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.06.2024
Počet zaměstnanců k 13.02.2024 545
Akcie v oběhu k 29.07.2024 48 000 205
MěnaUSD
Kontaktní informace
UliceOne World Trade Center, 22Nd Floor
MěstoNEW YORK
PSČ10007
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 123 323 241
Fax12123200245

Business Summary: Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Axsome Therapeutics Inc revenues increased 15% to $162.2M. Net loss increased 88% to $147.7M. Revenues reflect Novel therapies for management of CNS disorders segment increase from $46.7M to $162.2M. Higher net loss reflects Novel therapies for management of CNS disorders segment loss increase from $65.1M to $145.3M.
Odvětvová klasifikace
TRBC2012Biopharmaceuticals
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Research and Development in Biotechnology
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 19.09.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Chief Executive Officer, FounderHerriot Tabuteau5516.05.201801.01.2012
Chief Financial OfficerNick Pizzie4916.05.201816.05.2018
Chief Operating OfficerMark Jacobson40
Executive Vice President - Product StrategyLori Englebert46
Executive Vice President - Head of CommercialAri Maizel-
General CounselHunter Murdock44